MyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis

Inflammatory Bowel Diseases

Volumn 21, Issue 4, 2015, Pages 888-890

  Souza, Daniele G ^a,b   Senchenkova, Elena Y ^a,c   Russell, Janice ^a   Granger, D Neil ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

colitis; microbiota; MyD88; probiotics; thrombosis

Indexed keywords

CIPROFLOXACIN; CYTOKINE; DOCUSATE SODIUM; IMIPENEM; METRONIDAZOLE; MYELOID DIFFERENTIATION FACTOR 88; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; VANCOMYCIN; DEXTRAN SULFATE; MYD88 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTERIOLE; ARTERY THROMBOSIS; ARTICLE; COLON INJURY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL COLITIS; INFLAMMATION; INTESTINE FLORA; LEUKOCYTE MIGRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; SWISS WEBSTER MOUSE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; COLON; COMPLICATION; DIETARY SUPPLEMENT; DISEASE MODEL; IMMUNOLOGY; LEUKOCYTE; PHYSIOLOGY; THROMBOSIS;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; PROBIOTICS; THROMBOSIS;

EID: 84925459996     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000331     Document Type: Article

References (53)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl JMed. 2011;365:1713-1725.
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590-1605.
3. Lakatos PL, Lakatos L, Kiss LS, et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86:28-35.
4. Andrisani G, Guidi L, Papa A, et al. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2012;16:890-901.
5. Koutroumpakis EI, Tsiolakidou G, Koutroubakis IE. Risk of venous thromboembolism in patients with inflammatory bowel disease. Semin Thromb Hemost. 2013;39:461-468.
6. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-7236.
7. Yoshida H, Granger DN. Inflammatory bowel disease. A paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis. 2009;15: 1245-1255.
8. Anthoni C, Russell J, Wood KC, et al. Tissue factor. A mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis. J Exp Med. 2007;204:1595-1601.
9. Yan SL, Russell J, Harris NR, et al. Platelet abnormalities during colonic inflammation. Inflamm Bowel Dis. 2013;19:1245-1253.
10. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
11. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4:1051-1056.
12. Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr Opin Gastroenterol. 2009; 25:329-333.
13. Klimesova K, Kverka M, Zakostelska Z, et al. Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase Mdeficient mice. Inflamm Bowel Dis. 2013;19:1266-1277.
14. Vieira AT, Teixeira MM, Martins FS. The role of probiotics and prebiotics in inducing gut immunity. Front Immunol. 2013;4:445. eCollection 2013.
15. Reid G, Younes JA, Van der Mei HC, et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 2011;9:27-38.
16. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7:e34938.
17. Uronis JM, Arthur JC, Keku T, et al. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis. 2011;17:289-297.
18. Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1140-G1149.
19. Salim SY, Young PY, Lukowski CM, et al. VSL#3 probiotics provide protection against acute intestinal ischaemia/reperfusion injury. Benef Microbes. 2013;4:357-365.
20. So JS, Song MK, Kwon HK, et al. Lactobacillus casei enhances type II collagen/glucosamine-mediated suppression of inflammatory responses in experimental osteoarthritis. Life Sci. 2011;88:358-366.
21. Lam V, Su J, Koprowski S, et al. Intestinal microbiota determines severity of myocardial infarction in rats. FASEB J. 2012;26:1727-1735.
22. Stancu CS, Sanda GM, Deleanu M, et al. Probiotics determine hypolipidemic and antioxidant effects in hyperlipidemic hamsters. Mol Nutr Food Res. 2014;58:559-568.
23. Vowinkel T, Kalogeris TJ, Mori M, et al. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004;49:556-564.
24. Souza DG, Vieira AT, Soares AC, et al. The essential role of the intestinal microbiota in facilitating acute inflammatory responses. J Immunol. 2004; 173:4137-4146.
25. Pleasants JR. Gnotobiotics. In: Melby EC Jr, Altman NH Jr, eds. Handbook of Laboratory Animal Science. Cleveland, OH: CRC Press; 1974; 119.
26. Vieira AT, Fagundes CT, Alessandri AL, et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol. 2009;175:2382-2391.
27. Yoshida H, Russell J, Senchenkova EY, et al. Interleukin-1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol. 2010;177:2774-2781.
28. Rumbaut RE, Slaff DW, Burns AT. Microvascular thrombosis models in venules and arterioles in vivo. Microcirculation. 2005;12:259-274.
29. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385-391.
30. Strath M, Warren DJ, Sanderson SJ. Detection of eosinophils using an eosinophil peroxidase assay. Its use as an assay for eosinophil differentiation factors. J Immunol Methods. 1995;83:209-215.
31. Matos IM, Souza DG, Seabra DG, et al. Effects of tachykinin NK1 or PAF receptor blockade on the lung injury induced by scorpion venom in rats. Eur J Pharmacol. 1999;376:293-300.
32. Senchenkova EY, Komoto S, Russell J, et al. Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. Am J Pathol. 2013;183:173-181.
33. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-tomoderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105:2218-2227.
34. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001; 121:580-591.
35. Lampinen M, Rönnblom A, Amin K, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut. 2005;54: 1714-1720.
36. Ranganathan P, Jayakumar C, Manicassamy S, et al. CXCR2 knockout mice are protected against DSS-colitis-induced acute kidney injury and inflammation. Am J Physiol Ren Physiol. 2013;305:F1422-F1427.
37. Chu ZX, Chen HQ, Ma YL, et al. Lactobacillus plantarum prevents the upregulation of adhesion molecule expression in an experimental colitis model. Dig Dis Sci. 2010;55:2505-2513.
38. Angulo S, Llopis M, Antolín M, et al. Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2006;291: G1155-G1162.
39. Ajuebor MN, Kunkel SL, Hogaboam CM. The role of CCL3/macrophage inflammatory protein-1alpha in experimental colitis. Eur J Pharmacol. 2004;497:343-349.
40. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993:94:174-181.
41. Yan SL, Russell J, Granger DN. Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis. 2014;20:353-362.
42. Yoshida H, Yilmaz CE, Granger DN. Role of tumor necrosis factor-a in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis. 2011;17:2217-2223.
43. Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol. 2005;21:426-430.
44. Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res. 1999;19:757-760.
45. Thattaliyath B, Cykowski M, Jagadeeswaran P. Young thrombocytes initiate the formation of arterial thrombi in zebrafish. Blood. 2005;106:118-124.
46. Zhou JS, Rutherfurd KJ, Gill HS. Inability of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019 to induce human platelet aggregation in vitro. J Food Prot. 2005;68:2459-2464.
47. Schreiber O, Petersson J, Phillipson M, et al. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte-and plateletendothelial cell interactions. Am J Physiol Gastrointest Liver Physiol. 2009;296:G534-G542.
48. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.
49. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313-323.
50. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780-13785.
51. Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43:3380-3389.
52. Araki A, Kanai T, Ishikura T, et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol. 2005;40:16-23.
53. Jeon SG, Kayama H, Ueda Y, et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog. 2012;8:e1002714.